Cencora (COR)
| Market Cap | 44.38B |
| Revenue (ttm) | 276.54B |
| Net Income (ttm) | 1.85B |
| Shares Out | 199.45M |
| EPS (ttm) | 9.15 |
| PE Ratio | 24.32 |
| Forward PE | 15.75 |
| Dividend | $2.04 (0.92%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 1,421,149 |
| Open | 223.70 |
| Previous Close | 223.53 |
| Day's Range | 219.56 - 223.79 |
| 52-Week Range | 171.65 - 246.75 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 249.50 (+12.13%) |
| Earnings Date | Aug 8, 2024 |
About COR
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institu... [Read more]
Financial Performance
In 2023, Cencora's revenue was $262.17 billion, an increase of 9.89% compared to the previous year's $238.59 billion. Earnings were $1.75 billion, an increase of 2.74%.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for COR stock is "Buy." The 12-month stock price forecast is $249.5, which is an increase of 12.13% from the latest price.
News
AmerisourceBergen Specialty Group Substitute Notice of Data Incident to Affected Individuals
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group (ABSG) is issuing a substitute notice to individuals who may have been impacted by a data security incident. ABSG's parent company...
AmerisourceBergen Specialty Group Provides Substitute Notice of Data Incident to Affected Individuals
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--AmerisourceBergen Specialty Group, LLC (ABSG) is issuing notice to individuals who may have been impacted by a data security incident. ABSG's parent company previou...
Cencora notifies individuals about data stolen earlier this year
U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the comp...
Cencora to buy $400 million in stock back from Walgreens
Cencora has agreed to buy about $400 million in stock back from Walgreens Boots Alliance, the second time the pharmacy chain has reduced its stake in the company this year as it looks to free up cash ...
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance and Raises Fiscal 2024 Guidance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Sells Shares of Cencora for $400 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) pursuant to a share repurchase by Cencora in the amo...
Cencora To Host Inaugural ThinkLive Cell and Gene Therapy Summit
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, a global healthcare company, will convene leaders from across the healthcare and biopharmaceutical industries for its inaugural ThinkLive Cell and Gene The...
Cencora beats profit estimates on strong demand for costly specialty drugs
Cencora beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for costly specialty medicines that treat complex diseases such as cancer and rheumatoid arthritis.
Cencora Reports Fiscal 2024 Second Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 second quarter ended March 31, 2024, revenue increased 7.8 percent year-over-year to $68.4 bil...
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2024 on Wednesday, May 1, 2024, prior to the opening...
Cencora Announces Leadership Succession Plan
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that Steven H. Collis will retire as President and Chief Executive Officer of the Company and transition to the role of Ex...
Cencora says hit by cyber attack on its information systems
Cencora Inc said it has learned that data from its information systems had been exfiltrated, some of which may contain personal information, the drug distributor said in a filing on Tuesday.
Cencora's FormularyDecisions Launches Payer Resource for Cell and Gene Therapy Products
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--With the increasing number of cell and gene therapy (CGT) products in clinical development, Cencora's FormularyDecisions launched a new resource designed to provide...
Walgreens Boots pockets $992 mln after cutting Cencora stake for third time
U.S. drugstore chain Walgreens Boots Alliance on Wednesday said it has cut its stake in pharmaceutical distributor Cencora for the third time in just over six months, pocketing about $992 million.
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it has agreed to repurchase shares of its common stock from Walgreens Boots Alliance Holdings LLC in the amount of ap...
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that it has sold shares of Cencora, Inc. (NYSE: COR) common stock pursuant to Rule 144 for proceeds of ap...
Cencora Closes $500 Million Senior Notes Offering
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced the closing of its public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “No...
Cencora Releases 2023 ESG Report
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora (formerly AmerisourceBergen), a global healthcare company, released its 2023 Environmental, Social and Governance (ESG) Report. The report and the related E...
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it priced $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 (the “Notes”), in an underwritt...
Cencora raises profit outlook due to robust demand for high-priced specialty drug
Drug distributor Cencora raised its annual profit outlook on Wednesday, betting on strong demand for costly specialty medicines that treat diseases such as cancer and rheumatoid arthritis.
Cencora Reports Fiscal 2024 First Quarter Results
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 first quarter ended December 31, 2023, revenue increased 15.0 percent year-over-year to $72.3 ...
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2024 on Wednesday, January 31, 2024, prior to the ope...
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
BOSTON , Nov. 22, 2023 /PRNewswire/ -- Sapphiros, a platform company dedicated to building the next generation of consumer diagnostic technologies, is proud to announce it has entered into a distribut...
Walgreens sells shares of drug distributor Cencora
Drugstore chain Walgreens Boots Alliance Inc. WBA, -2.62% on Thursday said it had sold shares of drug distributor Cencora Inc. COR, +0.02% for approximately $424 million. Walgreens also entered into a...